MedTrace Logo

Hematopoietic Stem Cell Transplant Survivors Study

NCT02652052 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-01-15

No results posted yet for this study

Summary

The investigators hope to find the proof of principle concept from this pilot study so that the investigators can design a clinical trial based on the results of the explanatory hypothesis.

Conditions

  • Stem Cell Transplant

Interventions

OTHER

Standard of Care - Observation Only

Control Arm - Observation only

DRUG

Group 2: Quercetin

Quercetin - take four 250mg capsules daily (total 1000 mg daily) for 3 consecutive days.

DRUG

Group 2: Dasatinib

Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days

Sponsors & Collaborators

Principal Investigators

  • Suzanne R. Hayman, M.D. · Mayo Clinic in Rochester

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-01
Primary Completion
2023-05-23
Completion
2023-05-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02652052 on ClinicalTrials.gov